Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 19/20 | 0.56 |
| ▸ | TSHR | P16473 | 11/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.56 |
| ▸ | CASP1 | P29466 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 17/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 16/20 | 0.55 |
| ▸ | LMNA | P02545 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 14/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 13/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2605312 | 0.87 | CTSK (0.48) | SLC6A9CYP3A4TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL3711814 | 0.87 | CYP3A4 (0.54) | CYP3A4TSHRALDH1A1SMN1; SMN2CASP1 | |
| SCHEMBL2124675 | 0.83 | CYP3A4 (0.52) | CYP3A4TSHRALDH1A1SMN1; SMN2CASP1 | |
| SCHEMBL2124677 | 0.83 | CYP3A4 (0.52) | CYP3A4TSHRALDH1A1SMN1; SMN2CASP1 | |
| SCHEMBL3708435 | 0.82 | SLC6A9 (0.76) | SLC6A9 | |
| SCHEMBL2605325 | 0.82 | SLC6A9 (0.62) | SLC6A9 | |
| SCHEMBL2605333 | 0.82 | SLC6A9 (0.62) | SLC6A9 | |
| SCHEMBL2605332 | 0.82 | SLC6A9 (0.62) | SLC6A9 | |
| SCHEMBL2605317 | 0.75 | SLC6A9 (0.57) | SLC6A9CYP3A4TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL2605327 | 0.75 | SLC6A9 (1.00) | SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120094995-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2012-04-19 | — | — | US | disclosed |
| US-20120094995-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2012-04-19 | — | — | US | disclosed |
| WO-2010087762-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094995-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE COMPOUNDS AND USES THEREOF | SLC1A2, B4GALT1, SLC6A1 | SLC6A9 50/4885CYP3A4 838/4885TSHR 3969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.